Lucatumumab

Drug Profile

Lucatumumab

Alternative Names: CHIR-12.12; HCD-122

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novartis; XOMA
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoma; Multiple myeloma

Most Recent Events

  • 23 Jan 2013 Discontinued - Phase-I for Follicular lymphoma (combination therapy, second-line therapy or greater) in Belgium (IV)
  • 23 Jan 2013 Discontinued - Phase-I for Follicular lymphoma (combination therapy, second-line therapy or greater) in USA (IV)
  • 23 Jan 2013 Discontinued - Phase-I/II for Lymphoma in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top